Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Dystrophy: early-phase trial registry
1 of 4 indexed Retinal Dystrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Retinal Dystrophy: 4 US clinical trials tracked, 1 recruiting.
Retinal Dystrophy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is n-Lorem Foundation, running 1 of these trials.
Enrollment posture brief
Registry condition retinal-dystrophy
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Retinal Dystrophy lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Dystrophy is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Oral Metformin for Treatment of ABCA4 Retinopathy
National Eye Institute (NEI)
NCT04545736
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
PYC Therapeutics
NCT05902962
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
n-Lorem Foundation
NCT07177196
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Nanoscope Therapeutics
NCT05820100
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Dystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Dystrophy page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Retinal Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- n-Lorem Foundation sponsors the most Retinal Dystrophy trials on record, review their full trial history before evaluating a specific study. See n-Lorem Foundation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Dystrophy condition card totals 4 registered trials; most-linked intervention nL-PRPH2-001; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.